Shots:
Eli Lilly has acquired Engage Biologics, combining Engage’s Tethosome platform with Lilly’s genetic medicines capabilities & portfolio
As per the deal, Eli Lilly acquired Engage for ~$202M in cash, incl. an upfront payment and subsequent development milestones payments
The Tethosome platform is a non-viral DNA delivery system that combines engineered DNA payloads, lipid nanoparticles,…
